Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Wasserman

Showing results (211-220 of 259) with videos related to

Pageof 26
Sort By:
BMJ Quality & Safety|July 9, 2024
Frequency and preventability of adverse drug events in the outpatient settingRachel L Wasserman, Heba H Edrees, Mary G Amato, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|January 4, 2011
Prospective study of C1 esterase inhibitor in the treatment of successive acute abdominal and facial hereditary angioedema attacksRichard L Wasserman, Robyn J Levy, Againdra K Bewtra, et al.
Immunotherapy|July 29, 2016
Recombinant human hyaluronidase facilitated subcutaneous immunoglobulin treatment in pediatric patients with primary immunodeficiencies: long-term efficacy, safety and tolerabilityRichard L Wasserman, Isaac Melamed, Lisa Kobrynski, et al.
Clinical Pharmacokinetics|May 11, 2011
Pharmacokinetics of subcutaneous IgPro20 in patients with primary immunodeficiencyRichard L Wasserman, Isaac Melamed, Robert P Nelson, et al.
Frontiers in Immunology|July 26, 2021
Efficacy, Safety and Tolerability of a New 10% Intravenous Immunoglobulin for the Treatment of Primary ImmunodeficienciesElena E Perez, Jacques Hébert, Anne K Ellis, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|September 9, 2022
Information needs of patients considering oral immunotherapy for food allergyDouglas Paul Mack, Matthew Greenhawt, Paul J Turner, et al.
Clinical and Experimental Immunology|July 11, 2012
Evaluation of correlation between dose and clinical outcomes in subcutaneous immunoglobulin replacement therapyJ S Orange, B H Belohradsky, M Berger, et al.
Journal of Clinical Immunology|August 19, 2024
Long-Term Safety of Facilitated Subcutaneous Immunoglobulin 10% Treatment in US Clinical Practice in Patients with Primary Immunodeficiency Diseases: Results from a Post-Authorization Safety StudyArye Rubinstein, Mohsen Mabudian, Donald McNeil, et al.
Pediatrics|February 1, 1990
Lack of transmission of human immunodeficiency virus from infected children to their household contactsM F Rogers, C R White, R Sanders, et al.
International Journal of Medical Informatics|January 23, 2025
Development of a drug allergy alert tiering algorithm for penicillins and cephalosporinsRachel L Wasserman, Heba H Edrees, Diane L Seger, et al.
Pageof 26

Showing results (211-220 of 259) with videos related to

Sort By:
Pageof 26
BMJ Quality & Safety|July 9, 2024
Frequency and preventability of adverse drug events in the outpatient settingRachel L Wasserman, Heba H Edrees, Mary G Amato, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|January 4, 2011
Prospective study of C1 esterase inhibitor in the treatment of successive acute abdominal and facial hereditary angioedema attacksRichard L Wasserman, Robyn J Levy, Againdra K Bewtra, et al.
Immunotherapy|July 29, 2016
Recombinant human hyaluronidase facilitated subcutaneous immunoglobulin treatment in pediatric patients with primary immunodeficiencies: long-term efficacy, safety and tolerabilityRichard L Wasserman, Isaac Melamed, Lisa Kobrynski, et al.
Clinical Pharmacokinetics|May 11, 2011
Pharmacokinetics of subcutaneous IgPro20 in patients with primary immunodeficiencyRichard L Wasserman, Isaac Melamed, Robert P Nelson, et al.
Frontiers in Immunology|July 26, 2021
Efficacy, Safety and Tolerability of a New 10% Intravenous Immunoglobulin for the Treatment of Primary ImmunodeficienciesElena E Perez, Jacques Hébert, Anne K Ellis, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|September 9, 2022
Information needs of patients considering oral immunotherapy for food allergyDouglas Paul Mack, Matthew Greenhawt, Paul J Turner, et al.
Clinical and Experimental Immunology|July 11, 2012
Evaluation of correlation between dose and clinical outcomes in subcutaneous immunoglobulin replacement therapyJ S Orange, B H Belohradsky, M Berger, et al.
Journal of Clinical Immunology|August 19, 2024
Long-Term Safety of Facilitated Subcutaneous Immunoglobulin 10% Treatment in US Clinical Practice in Patients with Primary Immunodeficiency Diseases: Results from a Post-Authorization Safety StudyArye Rubinstein, Mohsen Mabudian, Donald McNeil, et al.
Pediatrics|February 1, 1990
Lack of transmission of human immunodeficiency virus from infected children to their household contactsM F Rogers, C R White, R Sanders, et al.
International Journal of Medical Informatics|January 23, 2025
Development of a drug allergy alert tiering algorithm for penicillins and cephalosporinsRachel L Wasserman, Heba H Edrees, Diane L Seger, et al.
Pageof 26